{"success":true,"data":{"pressRelease":{"id":"177211","rtpr_id":"nPnbLHq1ja-20261022","ticker":"PAIN","exchange":"","all_tickers":["PAIN"],"title":"Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides","author":"PR Newswire","published_at":"2026-10-22T13:01:13.083Z","article_body":"Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides\nPR Newswire\n\nTORONTO, Oct. 22, 2026\n\nInvestigational dissolving microneedle platform uses the therapeutic peptide\nas the structural material of the needle itself, with an initial focus on\nsports medicine and regenerative medicine\n\nTORONTO, Oct. 22, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp.\n(TSXV: PAIN) (\"Vector\" or the \"Company\") today introduced its investigational\npeptide-matrix microneedle technology, a dissolving microneedle platform\ndesigned to deliver peptides and other large-molecule therapeutics through the\nskin without conventional hypodermic injections. The technology extends\nVector's advanced transdermal delivery program and is designed to complement\nVector's cGMP-manufactured Rx peptides, manufactured using pharma-grade Active\nPharmaceutical Ingredients (API).\n\nThe Challenge: The Skin's Natural Barrier\n\nTherapeutic peptides, proteins and other large-molecule drugs are difficult to\ndeliver through the skin because of their size, hydrophilicity and\nsusceptibility to degradation. The skin's outer layer, the stratum corneum,\nblocks meaningful penetration of many peptides. As a result, injections remain\nthe standard route of administration, bringing needle aversion, inconvenience,\nadherence challenges and administration costs.\n\nA Different Approach: The Peptide Becomes the Needle\n\nRather than encapsulating the therapeutic peptide in a conventional carrier,\nVector's approach uses the peptide as a predominant structural component of a\nmicroscopic dissolvable needle. The projections are designed to penetrate the\nouter skin barrier and deposit peptide-rich material into the underlying\ntissue, where interstitial fluid dissolves the needle and releases the\npeptide. The platform design includes static patches and a handheld roller\nwith replaceable peptide-rich needle cartridges.\n\nPotential benefits include high drug loading with less inactive carrier\nmaterial; minimally invasive administration; simpler application in clinical\nor self-care settings; direct, localized deposition at the target tissue; and\nflexible designs for regenerative medicine, musculoskeletal care, wound\nmanagement, dermatology and selected systemic therapies. These potential\nbenefits remain subject to testing and validation.\n\nStrategic Fit and Market Opportunity\n\nAdvanced transdermal delivery is a core part of Vector's intellectual property\nstrategy. The Company's portfolio includes 15 pending patent applications\ncovering multi-route peptide and biologic delivery, lyophilized peptide\nformulations with point-of-care reconstitution, and advanced transdermal\ndelivery. Vector intends to focus the microneedle platform initially on sports\nmedicine and regenerative medicine, where targeted delivery to specific tissue\nis most relevant.\n\nAccording to Grand View Research, the global peptide therapeutics market was\nvalued at approximately US$140.9 billion in 2025 and is projected to reach\napproximately US$294.6 billion by 2033. Vector believes simpler administration\ncould support partnerships in peptide and therapeutic molecule delivery,\nclinician-administered treatments and patient-friendly therapy platforms.\n\n\"Peptides are among the most promising therapeutics in sports and regenerative\nmedicine, but most of them still require an injection,\" said Tom Bachinski\nChief Technology Office of Vector Science and Therapeutics. \"By making the\npeptide the needle itself, this platform is designed to place more of the\nactive molecule, with less carrier material, directly into the target tissue.\nWe believe targeted delivery could change orthopedics and sports medicine much\nthe way arthroscopy did, and it is a natural extension of our\ncGMP-manufactured Rx peptides.\"\n\n\"Making treatment simpler and less invasive is one of the most practical ways\nto improve patient care and adherence,\" said Tommy Thompson, Chairman of\nVector Science and Therapeutics and former U.S. Secretary of Health and Human\nServices. \"Vector is approaching this platform with discipline, starting with\nrigorous testing of safety, stability and performance, and working within the\nregulatory framework that will govern how it reaches patients.\"\n\nDevelopment Outlook\n\nVector intends to evaluate needle mechanical strength, peptide stability,\ndissolution behavior, dose uniformity, skin penetration and delivery\nperformance, alongside manufacturing scalability and regulatory requirements.\nThe technology is investigational and has not been approved by the U.S. Food\nand Drug Administration or any other regulatory authority. Its safety,\nclinical efficacy and commercial viability have not been established.\n\nAbout Vector Science and Therapeutics Corp.\n\nVector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology\ncompany advancing drug delivery technology and cGMP-manufactured Rx peptides\nfor the sports medicine, regenerative medicine, and pain management markets.\nVector's cGMP-manufactured Rx peptides, manufactured using pharma-grade Active\nPharmaceutical Ingredients (API), are not research-grade products: they are\nmanufactured under cGMP, FDA, and ISO-compliant conditions, Rx-labeled, and\nsold directly to physicians for physician use, rather than distributed through\nthe research-only channels associated with research-grade material. The\nCompany's product and intellectual property portfolio is focused on advanced\ntransdermal delivery, precision catheter systems, localized pain management,\npancreatic oncology, and smart wound care. Vector is headquartered in Mequon,\nWisconsin. For more information, visit https://vectorscience.co/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804055-1&h=1237898748&u=https%3A%2F%2Fvectorscience.co%2F&a=https%3A%2F%2Fvectorscience.co%2F)\n.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable Canadian securities legislation. Forward-looking information\nincludes, but is not limited to, statements regarding the design, potential\nbenefits, therapeutic uses and development of the Company's peptide-matrix\nmicroneedle technology, the Company's pending patent applications, anticipated\nregulatory pathways, potential partnerships, and the size and growth of the\npeptide therapeutics market. Forward-looking information is based on\nmanagement's current expectations and assumptions and is subject to known and\nunknown risks, uncertainties, and other factors that may cause actual results\nto differ materially from those expressed or implied, including the risk that\nthe technology does not perform as designed in testing, that peptide\nstability, dose uniformity or manufacturing at scale cannot be achieved, that\nrequired regulatory approvals are not obtained, that pending patent\napplications do not issue or do not provide meaningful protection, that\npartnerships are not concluded, or that the technology is not successfully\ncommercialized. Third-party market estimates vary by scope and methodology.\nReaders are cautioned not to place undue reliance on forward-looking\ninformation. The Company does not undertake any obligation to update\nforward-looking information except as required by applicable securities laws.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this news release.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vector-science-and-therapeutics-corp-introduces-peptide-matrix-microneedle-technology-for-targeted-transdermal-delivery-of-peptides-302916850.html\n(https://www.prnewswire.com/news-releases/vector-science-and-therapeutics-corp-introduces-peptide-matrix-microneedle-technology-for-targeted-transdermal-delivery-of-peptides-302916850.html)\n\nSOURCE Vector Sciences & Therapeutics\n\n\n\nVector Science and Therapeutics Corp.,  investor@vectorscience.co, www.vectorscience.co\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1731895/Vector-Sciences-Therapeutics-Logo.jpg?id=OA3033645\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbLHq1ja-20261022","title":"Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides","author":"PR Newswire","ticker":"PAIN","created":"2026-10-22T13:01:13.083Z","tickers":["PAIN"],"exchange":"","article_body":"Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides\nPR Newswire\n\nTORONTO, Oct. 22, 2026\n\nInvestigational dissolving microneedle platform uses the therapeutic peptide\nas the structural material of the needle itself, with an initial focus on\nsports medicine and regenerative medicine\n\nTORONTO, Oct. 22, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp.\n(TSXV: PAIN) (\"Vector\" or the \"Company\") today introduced its investigational\npeptide-matrix microneedle technology, a dissolving microneedle platform\ndesigned to deliver peptides and other large-molecule therapeutics through the\nskin without conventional hypodermic injections. The technology extends\nVector's advanced transdermal delivery program and is designed to complement\nVector's cGMP-manufactured Rx peptides, manufactured using pharma-grade Active\nPharmaceutical Ingredients (API).\n\nThe Challenge: The Skin's Natural Barrier\n\nTherapeutic peptides, proteins and other large-molecule drugs are difficult to\ndeliver through the skin because of their size, hydrophilicity and\nsusceptibility to degradation. The skin's outer layer, the stratum corneum,\nblocks meaningful penetration of many peptides. As a result, injections remain\nthe standard route of administration, bringing needle aversion, inconvenience,\nadherence challenges and administration costs.\n\nA Different Approach: The Peptide Becomes the Needle\n\nRather than encapsulating the therapeutic peptide in a conventional carrier,\nVector's approach uses the peptide as a predominant structural component of a\nmicroscopic dissolvable needle. The projections are designed to penetrate the\nouter skin barrier and deposit peptide-rich material into the underlying\ntissue, where interstitial fluid dissolves the needle and releases the\npeptide. The platform design includes static patches and a handheld roller\nwith replaceable peptide-rich needle cartridges.\n\nPotential benefits include high drug loading with less inactive carrier\nmaterial; minimally invasive administration; simpler application in clinical\nor self-care settings; direct, localized deposition at the target tissue; and\nflexible designs for regenerative medicine, musculoskeletal care, wound\nmanagement, dermatology and selected systemic therapies. These potential\nbenefits remain subject to testing and validation.\n\nStrategic Fit and Market Opportunity\n\nAdvanced transdermal delivery is a core part of Vector's intellectual property\nstrategy. The Company's portfolio includes 15 pending patent applications\ncovering multi-route peptide and biologic delivery, lyophilized peptide\nformulations with point-of-care reconstitution, and advanced transdermal\ndelivery. Vector intends to focus the microneedle platform initially on sports\nmedicine and regenerative medicine, where targeted delivery to specific tissue\nis most relevant.\n\nAccording to Grand View Research, the global peptide therapeutics market was\nvalued at approximately US$140.9 billion in 2025 and is projected to reach\napproximately US$294.6 billion by 2033. Vector believes simpler administration\ncould support partnerships in peptide and therapeutic molecule delivery,\nclinician-administered treatments and patient-friendly therapy platforms.\n\n\"Peptides are among the most promising therapeutics in sports and regenerative\nmedicine, but most of them still require an injection,\" said Tom Bachinski\nChief Technology Office of Vector Science and Therapeutics. \"By making the\npeptide the needle itself, this platform is designed to place more of the\nactive molecule, with less carrier material, directly into the target tissue.\nWe believe targeted delivery could change orthopedics and sports medicine much\nthe way arthroscopy did, and it is a natural extension of our\ncGMP-manufactured Rx peptides.\"\n\n\"Making treatment simpler and less invasive is one of the most practical ways\nto improve patient care and adherence,\" said Tommy Thompson, Chairman of\nVector Science and Therapeutics and former U.S. Secretary of Health and Human\nServices. \"Vector is approaching this platform with discipline, starting with\nrigorous testing of safety, stability and performance, and working within the\nregulatory framework that will govern how it reaches patients.\"\n\nDevelopment Outlook\n\nVector intends to evaluate needle mechanical strength, peptide stability,\ndissolution behavior, dose uniformity, skin penetration and delivery\nperformance, alongside manufacturing scalability and regulatory requirements.\nThe technology is investigational and has not been approved by the U.S. Food\nand Drug Administration or any other regulatory authority. Its safety,\nclinical efficacy and commercial viability have not been established.\n\nAbout Vector Science and Therapeutics Corp.\n\nVector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology\ncompany advancing drug delivery technology and cGMP-manufactured Rx peptides\nfor the sports medicine, regenerative medicine, and pain management markets.\nVector's cGMP-manufactured Rx peptides, manufactured using pharma-grade Active\nPharmaceutical Ingredients (API), are not research-grade products: they are\nmanufactured under cGMP, FDA, and ISO-compliant conditions, Rx-labeled, and\nsold directly to physicians for physician use, rather than distributed through\nthe research-only channels associated with research-grade material. The\nCompany's product and intellectual property portfolio is focused on advanced\ntransdermal delivery, precision catheter systems, localized pain management,\npancreatic oncology, and smart wound care. Vector is headquartered in Mequon,\nWisconsin. For more information, visit https://vectorscience.co/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804055-1&h=1237898748&u=https%3A%2F%2Fvectorscience.co%2F&a=https%3A%2F%2Fvectorscience.co%2F)\n.\n\nCautionary Note Regarding Forward-Looking Information\n\nThis news release contains \"forward-looking information\" within the meaning of\napplicable Canadian securities legislation. Forward-looking information\nincludes, but is not limited to, statements regarding the design, potential\nbenefits, therapeutic uses and development of the Company's peptide-matrix\nmicroneedle technology, the Company's pending patent applications, anticipated\nregulatory pathways, potential partnerships, and the size and growth of the\npeptide therapeutics market. Forward-looking information is based on\nmanagement's current expectations and assumptions and is subject to known and\nunknown risks, uncertainties, and other factors that may cause actual results\nto differ materially from those expressed or implied, including the risk that\nthe technology does not perform as designed in testing, that peptide\nstability, dose uniformity or manufacturing at scale cannot be achieved, that\nrequired regulatory approvals are not obtained, that pending patent\napplications do not issue or do not provide meaningful protection, that\npartnerships are not concluded, or that the technology is not successfully\ncommercialized. Third-party market estimates vary by scope and methodology.\nReaders are cautioned not to place undue reliance on forward-looking\ninformation. The Company does not undertake any obligation to update\nforward-looking information except as required by applicable securities laws.\n\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that\nterm is defined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this news release.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vector-science-and-therapeutics-corp-introduces-peptide-matrix-microneedle-technology-for-targeted-transdermal-delivery-of-peptides-302916850.html\n(https://www.prnewswire.com/news-releases/vector-science-and-therapeutics-corp-introduces-peptide-matrix-microneedle-technology-for-targeted-transdermal-delivery-of-peptides-302916850.html)\n\nSOURCE Vector Sciences & Therapeutics\n\n\n\nVector Science and Therapeutics Corp.,  investor@vectorscience.co, www.vectorscience.co\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1731895/Vector-Sciences-Therapeutics-Logo.jpg?id=OA3033645\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-22T13:01:13.148941853Z","server_sent_at_ms":1792674073148},"received_at":"2026-10-22T13:01:13.215Z","source_url":"https://www.prnewswire.com/news-releases/vector-science-and-therapeutics-corp-introduces-peptide-matrix-microneedle-technology-for-targeted-transdermal-delivery-of-peptides-302916850.html"},"analysis":{"id":"165164","press_release_id":"177211","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["technology is investigational and not FDA-approved; safety and clinical efficacy not established","patent applications are pending, not granted","headline market-size figures are third-party estimates, not company revenue"],"eventType":"product_launch","narrative":"Vector Science and Therapeutics (TSXV: PAIN) introduced an investigational peptide-matrix microneedle platform that uses the therapeutic peptide itself as the structural material of a dissolving needle for transdermal delivery.\n\nThe company plans an initial focus on sports medicine and regenerative medicine, supported by 15 pending patent applications across multi-route peptide delivery and transdermal technologies.\n\nThe technology remains unapproved and unvalidated: FDA approval has not been sought or received, and safety, efficacy, and commercial viability have not been established.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early-stage platform announcement from a micro-cap -- novel needle-free peptide delivery concept but years from clinical validation."},"keyFigures":{"customDimensions":{"peptide_market_2025_usd":"approximately US$140.9 billion","pending_patent_applications":15,"peptide_market_2033_projection_usd":"approximately US$294.6 billion"}},"quotedText":"By making the peptide the needle itself, this platform is designed to place more of the active molecule, with less carrier material, directly into the target tissue.","namedEntities":{"people":[{"name":"Tom Bachinski","role":"Chief Technology Officer"},{"name":"Tommy Thompson","role":"Chairman, former U.S. Secretary of Health and Human Services"}],"products":["Peptide-matrix microneedle technology","cGMP-manufactured Rx peptides"],"companies":[{"name":"Vector Science and Therapeutics Corp.","ticker":"PAIN"},{"name":"Grand View Research","relationship":"market research source"}],"dollarAmounts":[{"amount":"US$140.9 billion","context":"global peptide therapeutics market value in 2025 (Grand View Research)"},{"amount":"US$294.6 billion","context":"projected peptide therapeutics market size by 2033"}]},"materialImpact":{"score":2,"reasoning":"Introduction of an investigational, pre-FDA drug-delivery platform with no revenue, clinical, or regulatory milestone yet. Notable IP positioning (15 pending patent applications) but all benefits remain unvalidated."},"tickerRelevance":{"others":[],"primary":"PAIN"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap TSXV","eventGravity":"preclinical platform introduction, no regulatory or revenue milestone","issuerAuthored":true,"householdBrandBoost":"minor via Tommy Thompson name recognition"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Vector Science and Therapeutics (TSXV: PAIN) introduced an investigational peptide-matrix microneedle platform that uses the therapeutic peptide itself as the structural material of a dissolving needle for transdermal delivery.\n\nThe company plans an initial focus on sports medicine and regenerative medicine, supported by 15 pending patent applications across multi-route peptide delivery and transdermal technologies.\n\nThe technology remains unapproved and unvalidated: FDA approval has not been sought or received, and safety, efficacy, and commercial viability have not been established.","key_figures":{"customDimensions":{"peptide_market_2025_usd":"approximately US$140.9 billion","pending_patent_applications":15,"peptide_market_2033_projection_usd":"approximately US$294.6 billion"}},"named_entities":{"people":[{"name":"Tom Bachinski","role":"Chief Technology Officer"},{"name":"Tommy Thompson","role":"Chairman, former U.S. Secretary of Health and Human Services"}],"products":["Peptide-matrix microneedle technology","cGMP-manufactured Rx peptides"],"companies":[{"name":"Vector Science and Therapeutics Corp.","ticker":"PAIN"},{"name":"Grand View Research","relationship":"market research source"}],"dollarAmounts":[{"amount":"US$140.9 billion","context":"global peptide therapeutics market value in 2025 (Grand View Research)"},{"amount":"US$294.6 billion","context":"projected peptide therapeutics market size by 2033"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T13:01:18.580Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap TSXV","eventGravity":"preclinical platform introduction, no regulatory or revenue milestone","issuerAuthored":true,"householdBrandBoost":"minor via Tommy Thompson name recognition"}},"durationMs":5345,"modelName":"glm-5.3-flashx"}}